Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 02, 2026
Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
Journal: JCO oncology practice
Published: June 29, 2026
Cellular Therapies in Solid Tumors: Are We Ready for Primetime?
Journal: JCO oncology practice
Published: May 20, 2026
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 08, 2026
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.
Journal: The New England journal of medicine
Published: May 06, 2026
Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC.
Journal: Cancer treatment and research communications
Published: March 02, 2026
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials.
Journal: BMJ oncology
Published: December 16, 2025
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.
Journal: Nature medicine
Published: November 25, 2025
Mutant Selective T-Cell Receptor Therapy for Solid Tumors.
Journal: Molecular cancer therapeutics
Published: November 18, 2025
Disrupted molecular glue complex drives RAS inhibitor resistance.
Journal: Cell
Published: June 03, 2025
Contrastive learning uncovers cellular interactions and morphologies in the tumor microenvironment of lung adenocarcinoma linked to immunotherapy response.
Journal: Scientific reports
Published: February 18, 2025
Last Updated: 09/26/2026